Development
Vitro, S.A.B. de C.V.
VITOF
$0.15
-$0.51-77.27%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 625.66M | 622.38M | 602.11M | 595.83M | 622.93M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 625.66M | 622.38M | 602.11M | 595.83M | 622.93M |
| Cost of Revenue | 477.48M | 462.24M | 448.71M | 441.17M | 471.44M |
| Gross Profit | 148.18M | 160.14M | 153.40M | 154.66M | 151.49M |
| SG&A Expenses | 112.69M | 117.19M | 113.69M | 113.20M | 113.61M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 4.04M | -1.65M | 4.05M | 9.14M | 113.00K |
| Total Operating Expenses | 594.21M | 577.77M | 566.44M | 563.51M | 585.16M |
| Operating Income | 31.45M | 44.61M | 35.66M | 32.32M | 37.77M |
| Income Before Tax | 8.21M | 34.98M | 32.58M | -61.00K | 11.51M |
| Income Tax Expenses | -6.09M | -834.00K | -3.65M | -6.03M | 27.41M |
| Earnings from Continuing Operations | 14.31M | 35.81M | 36.23M | 5.97M | -15.90M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 44.00K | 140.00K | 50.00K | 168.00K | 102.00K |
| Net Income | 14.35M | 35.95M | 36.28M | 6.13M | -15.80M |
| EBIT | 31.45M | 44.61M | 35.66M | 32.32M | 37.77M |
| EBITDA | 70.62M | 81.46M | 72.32M | 42.55M | 74.10M |
| EPS Basic | 0.03 | 0.08 | 0.08 | 0.05 | -0.03 |
| Normalized Basic EPS | 0.01 | 0.05 | 0.05 | 0.11 | 0.01 |
| EPS Diluted | 0.03 | 0.08 | 0.08 | 0.05 | -0.03 |
| Normalized Diluted EPS | 0.01 | 0.05 | 0.05 | 0.11 | 0.01 |
| Average Basic Shares Outstanding | 478.33M | 449.38M | 453.44M | 120.61M | 526.70M |
| Average Diluted Shares Outstanding | 478.33M | 449.38M | 453.44M | 120.61M | 526.70M |
| Dividend Per Share | -- | -- | -- | 0.06 | -- |
| Payout Ratio | 0.00% | 83.45% | -- | 163.03% | -- |